Atai Beckley N.V (ATAI)
$
3.82
-0.24 (-6.28%)
Key metrics
Financial statements
Free cash flow per share
-0.4152
Market cap
720.5 Million
Price to sales ratio
238.7500
Debt to equity
0.0185
Current ratio
7.8981
Income quality
0.5152
Average inventory
0
ROE
-1.0786
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company focused on developing therapeutic candidates aimed at addressing various mental health disorders. The operating expenses amount to $102,999,000.00 encompassing various operational costs incurred. The total costs and expenses for the company are $102,999,000.00 reflecting its overall spending. Among its therapeutic candidates are PCN-101, a subcutaneous formulation of R-ketamine for treating treatment-resistant depression (TRD); RL-007, a modulator targeting cholinergic, glutamatergic, and GABA-B receptors to address cognitive impairment related to schizophrenia; and DMX-1002, an oral formulation of ibogaine targeting opioid use disorder (OUD). Other notable candidates include GRX-917, aimed at treating generalized anxiety disorder, and NN-101, a novel intranasal formulation of N-acetylcysteine for mild traumatic brain injuries. The net income ratio is -484.64 reflecting the company's profitability margin, while the earnings per share (EPS) is reported at -$0.93 indicating profitability on a per-share basis. Additionally, the weighted average number of diluted shares outstanding is 160,159,983.00 reflecting potential dilution effects. Atai Life Sciences N.V., formerly known as Adripa Holding B.V., was founded in 2018 and is headquartered in Berlin, Germany. The stock is affordable at $4.95 making it suitable for budget-conscious investors. With a market capitalization of $720,547,500.00 the company is classified as a small-cap player. It is a key player in the Medical - Pharmaceuticals industry, contributing significantly to the overall market landscape. The stock also has a high average trading volume of 4,357,198.00 indicating strong liquidity, and it belongs to the Healthcare sector, driving innovation and growth. These characteristics underscore the company's role in reshaping the therapeutic landscape for mental health disorders while offering potential investment opportunities.
Is Atai Beckley N.V (ATAI) a good investment?
Investing in Atai Beckley N.V (ATAI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Atai Beckley N.V (ATAI)'s stock forecast?
Analysts predict Atai Beckley N.V stock to fluctuate between $1.15 (low) and $6.75 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Atai Beckley N.V's market capitalization?
As of 2026-03-13, Atai Beckley N.V's market cap is $720,547,500, based on 188,625,000 outstanding shares.
How does Atai Beckley N.V compare to competitors like WAL-MART STORES INC?
Compared to WAL-MART STORES INC, Atai Beckley N.V has a Lower Market-Cap, indicating a difference in performance.
Does Atai Beckley N.V pay dividends?
Atai Beckley N.V pays dividends. The current dividend yield is 30.17%, with a payout of $6 per share.
How can I buy Atai Beckley N.V (ATAI) stock?
To buy Atai Beckley N.V (ATAI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATAI. Place an order (Market, Limit, etc.).
What is the best time to invest in Atai Beckley N.V?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Atai Beckley N.V perform in the last earnings report?
Revenue: $308,000 | EPS: -$0.93 | Growth: 272%.
Where can I find Atai Beckley N.V's investor relations reports?
Visit https://www.ataibeckley.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Atai Beckley N.V?
You can explore historical data from here
What is the all-time high and low for Atai Beckley N.V stock?
All-time high: $17.90 (2021-09-08) | All-time low: $1.03 (2023-12-01).
What are the key trends affecting Atai Beckley N.V stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
proactiveinvestors.com
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has highlighted progress across its clinical pipeline and reaffirmed its financial outlook during its 2026 Virtual Investor Day, outlining plans to advance its lead candidate BPL-003 into Phase 3 trials for treatment-resistant depression while continuing development of additional mental health therapies. The clinical-stage biotechnology company said it remains on track to initiate two parallel Phase 3 pivotal studies of BPL-003, a mebufotenin benzoate nasal spray, in the second quarter of 2026 following a successful End-of-Phase 2 meeting with the US Food and Drug Administration.
seekingalpha.com
AtaiBeckley Inc. (ATAI) Analyst/Investor Day Transcript
proactiveinvestors.com
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has reported its fourth quarter and full-year 2025 financial results, highlighting progress across several clinical programs targeting mental health disorders and outlining upcoming milestones for its pipeline. The clinical-stage biotechnology company said it remains on track to initiate a Phase 3 pivotal program for BPL-003, its mebufotenin benzoate nasal spray for treatment-resistant depression (TRD), in the second quarter of 2026.
globenewswire.com
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced fourth quarter and full year 2025 financial results and provided key regulatory, clinical and business updates.
proactiveinvestors.com
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) has reported positive topline results from an exploratory Phase 2a trial evaluating its oral R-MDMA candidate, EMP-01, in adults with social anxiety disorder (SAD), with the study meeting its primary safety objective and showing encouraging efficacy signals. The clinical-stage biotechnology company said the randomized, double-blind, placebo-controlled study enrolled 71 adults with moderate-to-severe SAD across seven sites in the United Kingdom.
globenewswire.com
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m.
marketbeat.com
Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key predictions about trial outcomes. Alongside the continued proliferation of technology within the drug development space, companies with a focus on obesity, rare diseases, and oncology applications saw commercial achievements.
proactiveinvestors.com
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it participated in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held January 12 to 15, 2026, in Nassau, The Bahamas, where the company presented two scientific posters and delivered a Hot Topic Presentation. The clinical-stage biotechnology company said the presentations included new clinical and preclinical data related to its mental health development programs.
globenewswire.com
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), which took place on January 12 - 15, 2026 in Nassau, The Bahamas. The Company presented new clinical and preclinical data supporting its development of transformative mental health therapies in two poster presentations and a Hot Topic Presentation.
zacks.com
ATAI, BHR and BZH have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.
See all news
